LIVIVO - Search results -

Search results

Result 1 - 10 of total 83

Search options

Article ; Online: Regulatory B Cells-Immunopathological and Prognostic Potential in Humans.

Veh, Johanna / Ludwig, Carolin / Schrezenmeier, Hubert / Jahrsdörfer, Bernd

2024 Volume 13, Issue 4

Abstract: The aim of the following review is to shed light on the putative role of regulatory B cells (Bregs) in ... ...

Abstract	The aim of the following review is to shed light on the putative role of regulatory B cells (Bregs) in various
MeSH term(s)	Humans ; Mice ; Animals ; Interleukin-10/metabolism ; B-Lymphocytes, Regulatory ; Prognosis ; Cytokines/metabolism ; Inflammation/metabolism ; Immunosuppressive Agents/therapeutic use
Chemical Substances	Interleukin-10 (130068-27-8) ; Cytokines ; Immunosuppressive Agents
Language	English
Publishing date	2024-02-18
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2661518-6
ISSN	2073-4409 ; 2073-4409
ISSN (online)	2073-4409
ISSN	2073-4409
DOI	10.3390/cells13040357
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Book ; Thesis: Beeinflußbarkeit der leukozytären Aufnahme von Antisense-Oligodesoxynukleotiden gegen Tumor-Nekrose-Faktor-alpha in Vollblut

Jahrsdörfer, Bernd

2000

Language	German
Size	141 S. : Ill., graph. Darst., 21 cm
Publishing country	Germany
Document type	Book ; Thesis
Thesis / German Habilitation thesis	München, Univ., Diss., 2000
HBZ-ID	HT012889815
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
2001 D 55	order for loan	Magazin

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: [No title information]

Veh, Johanna / Ludwig, Carolin / Schrezenmeier, Hubert / Jahrsdörfer, Bernd

Transfusionsmedizin

2023 Volume 13, Issue 03, Page(s) 120–133

Abstract: Regulatorische B-Zellen (Bregs) stellen eine heterogene Gruppe von B-Zellen dar, welche in der Lage sind, inflammatorische Immunantworten zu unterdrücken. Bregs tragen damit zur Aufrechterhaltung von Toleranz und ...

Abstract	Regulatorische B-Zellen (Bregs) stellen eine heterogene Gruppe von B-Zellen dar, welche in der Lage sind, inflammatorische Immunantworten zu unterdrücken. Bregs tragen damit zur Aufrechterhaltung von Toleranz und zur Immunhomöostase bei, indem sie laufende Immunreaktionen räumlich und zeitlich begrenzen. Die herausragende Rolle von Bregs bei der Eindämmung pathologisch überschießender Entzündungsreaktionen, mit der sowohl Allergien, Autoimmunerkrankungen und Transplantatabstoßungen, aber auch Infektionen, Neoplasien und Stoffwechselerkrankungen einhergehen können, wurde in einer Vielzahl von Tiermodellen nachgewiesen. Die ersten Studien zu Bregs identifizierten IL-10 als funktionelles Schlüsselmolekül, weshalb die murine IL-10-produzierende B10-Zelle noch immer als Prototyp für Bregs gilt und IL-10 bei der Suche nach humanen Äquivalenten für Bregs lange im Vordergrund stand. In den letzten 2 Jahrzehnten wurde jedoch eine ganze Reihe weiterer Moleküle entdeckt, die – teilweise auch ausschließlich in humanen Bregs – zu ihrer immunsuppressiven Funktion beitragen können. Zu diesem erweiterten Arsenal gehören zum einen weitere entzündungshemmende Zytokine wie IL-35 und TGF-β, aber auch Enzyme wie Granzym B, CD39/CD73 und IDO, sowie Zelloberflächenproteine wie CD1d, PD-L1 und CD25. Ziel des vorliegenden Übersichtsartikels soll es sein, die mutmaßliche Rolle von Bregs insbesondere bei unterschiedlichen Humanpathologien zu beleuchten und dabei ihre potenzielle therapeutische und prognostische Relevanz hervorzuheben.
Keywords	Regulatorische B-Zelle (Breg) ; Interleukin 10 ; GraB-Zelle ; Granzym B ; Immunsuppression ; Regulatory B cell (Breg) ; Interleukin 10 ; GraB cell ; granzyme B ; immunosuppression
Language	German
Publishing date	2023-08-01
Publisher	Georg Thieme Verlag
Publishing place	Stuttgart ; New York
Document type	Article
ZDB-ID	2599278-8
ISSN	2191-8813 ; 2191-8805
ISSN (online)	2191-8813
ISSN	2191-8805
DOI	10.1055/a-2010-5218
Database	Thieme publisher's database

In stock of ZB MED Cologne/Königswinter

Zs.A 6977: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Immune Plasma for the Treatment of COVID-19: Lessons Learned so far.

Schrezenmeier, Hubert / Hoffmann, Simone / Hofmann, Henrike / Appl, Thomas / Jahrsdörfer, Bernd / Seifried, Erhard / Körper, Sixten

Hamostaseologie

2023 Volume 43, Issue 1, Page(s) 67–74

Abstract: COVID-19 convalescent plasma (CCP) has been explored as one of the treatment options for COVID-19. Results of many cohort studies and clinical trials have been recently published. At first glance, the results of the CCP studies appear to be inconsistent. ...

Abstract	COVID-19 convalescent plasma (CCP) has been explored as one of the treatment options for COVID-19. Results of many cohort studies and clinical trials have been recently published. At first glance, the results of the CCP studies appear to be inconsistent. However, it became clear that CCP is not beneficial if CCP with low anti-SARS-CoV-2 antibody concentrations is used, if it is administered late in advanced disease stages, and to patients who already mounted an antibody response against SARS-CoV-2 at the time of CCP transfusion. On the other hand, CCP may prevent progression to severe COVID-19 when very high-titer CCP is given early in vulnerable patients. Immune escape of new variants is a challenge for passive immunotherapy. While new variants of concern developed resistance to most clinically used monoclonal antibodies very rapidly, immune plasma from individuals immunized by both a natural SARS-CoV-2 infection and SARS-CoV-2 vaccination retained neutralizing activity against variants. This review briefly summarizes the evidence on CCP treatment to date and identifies further research needs. Ongoing research on passive immunotherapy is not only relevant for improving care for vulnerable patients in the ongoing SARS-CoV-2 pandemic, but even more as a model for passive immunotherapy in case of future pandemics with a newly evolving pathogen. Compared to other drugs, which must be newly developed in a pandemic (e.g., monoclonal antibodies, antiviral drugs), convalescent plasma is rapidly available, inexpensive to produce, and can be adaptive to viral evolution by selection of contemporary convalescent donors.
MeSH term(s)	Humans ; COVID-19 ; SARS-CoV-2/physiology ; COVID-19 Vaccines ; COVID-19 Serotherapy ; Antibodies, Monoclonal
Chemical Substances	COVID-19 Vaccines ; Antibodies, Monoclonal
Language	English
Publishing date	2023-02-20
Publishing country	Germany
Document type	Review ; Journal Article
ZDB-ID	801512-0
ISSN	2567-5761 ; 0720-9355
ISSN (online)	2567-5761
ISSN	0720-9355
DOI	10.1055/a-1987-3682
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1631: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Nachweis von Antikörpern gegen SARS-CoV-2

Jahrsdörfer, Bernd / Schrezenmeier, Hubert

Transfusionsmedizin

2021 Volume 11, Issue 03, Page(s) 182–187

Abstract: Der folgende Beitrag gibt einen Überblick über kommerziell erhältliche Testsysteme zur Untersuchung von Probenmaterial aus Blut auf verschiedene Antikörper gegen SARS-CoV-2. Dabei wird auch auf mögliche Anwendungen solcher Testungen eingegangen, ... ...

Abstract	Der folgende Beitrag gibt einen Überblick über kommerziell erhältliche Testsysteme zur Untersuchung von Probenmaterial aus Blut auf verschiedene Antikörper gegen SARS-CoV-2. Dabei wird auch auf mögliche Anwendungen solcher Testungen eingegangen, angefangen von Seroprävalenz- und Longitudinalstudien über das Screening potenzieller Rekonvaleszenzplasmaspender bis hin zum Monitoring der humoralen Immunantwort nach Impfung gegen SARS-CoV-2.
Keywords	SARS-CoV-2 ; COVID-19 ; Antikörper ; Neutralisationstest ; Rezeptorbindungsdomäne ; SARS-CoV-2 ; COVID-19 ; antibody ; neutralization test ; receptor binding domain
Language	German
Publishing date	2021-08-01
Publisher	Georg Thieme Verlag KG
Publishing place	Stuttgart ; New York
Document type	Article
ZDB-ID	2599278-8
ISSN	2191-8813 ; 2191-8805
ISSN (online)	2191-8813
ISSN	2191-8805
DOI	10.1055/a-1342-0995
Database	Thieme publisher's database

In stock of ZB MED Cologne/Königswinter

Zs.A 6977: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Phorbol-12-myristate-13-acetate is a potent enhancer of B cells with a granzyme B

Veh, Johanna / Mangold, Charlotte / Felsen, Anja / Ludwig, Carolin / Gerstner, Lisa / Reinhardt, Peter / Schrezenmeier, Hubert / Fabricius, Dorit / Jahrsdörfer, Bernd

Frontiers in immunology

2023 Volume 14, Page(s) 1194880

Abstract: Introduction: The infusion of : Methods: Previously, we developed a protocol for the generation of a novel population of regulatory B cells, which are characterized by secretion of enzymatically active granzyme B (: Results: In the present work we ...

Abstract	Introduction: The infusion of Methods: Previously, we developed a protocol for the generation of a novel population of regulatory B cells, which are characterized by secretion of enzymatically active granzyme B ( Results: In the present work we demonstrated that phorbol-12-myristate-13-acetate (PMA/TPA), a phorbol ester with a particular analogy to the second messenger diacylglycerol (DAG), is a potent enhancer of IL-21-induced differentiation of pre-activated B cells into Discussion: Given that PMA/TPA has already undergone encouraging clinical testing in patients with certain haematological diseases, our results suggest that PMA/TPA may be a safe and feasible alternative for
MeSH term(s)	Humans ; B-Lymphocytes, Regulatory/drug effects ; Granzymes ; Tetradecanoylphorbol Acetate/pharmacology
Chemical Substances	Granzymes (EC 3.4.21.-) ; Tetradecanoylphorbol Acetate (NI40JAQ945) ; phorbolol myristate acetate (56937-68-9)
Language	English
Publishing date	2023-07-27
Publishing country	Switzerland
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2606827-8
ISSN	1664-3224 ; 1664-3224
ISSN (online)	1664-3224
ISSN	1664-3224
DOI	10.3389/fimmu.2023.1194880
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Immune Plasma for the Treatment of COVID-19: Lessons Learned so far

Schrezenmeier, Hubert / Hoffmann, Simone / Hofmann, Henrike / Appl, Thomas / Jahrsdörfer, Bernd / Seifried, Erhard / Körper, Sixten

Hämostaseologie

2023 Volume 43, Issue 01, Page(s) 67–74

Abstract	COVID-19 convalescent plasma (CCP) has been explored as one of the treatment options for COVID-19. Results of many cohort studies and clinical trials have been recently published. At first glance, the results of the CCP studies appear to be inconsistent. However, it became clear that CCP is not beneficial if CCP with low anti-SARS-CoV-2 antibody concentrations is used, if it is administered late in advanced disease stages, and to patients who already mounted an antibody response against SARS-CoV-2 at the time of CCP transfusion. On the other hand, CCP may prevent progression to severe COVID-19 when very high-titer CCP is given early in vulnerable patients. Immune escape of new variants is a challenge for passive immunotherapy. While new variants of concern developed resistance to most clinically used monoclonal antibodies very rapidly, immune plasma from individuals immunized by both a natural SARS-CoV-2 infection and SARS-CoV-2 vaccination retained neutralizing activity against variants. This review briefly summarizes the evidence on CCP treatment to date and identifies further research needs. Ongoing research on passive immunotherapy is not only relevant for improving care for vulnerable patients in the ongoing SARS-CoV-2 pandemic, but even more as a model for passive immunotherapy in case of future pandemics with a newly evolving pathogen. Compared to other drugs, which must be newly developed in a pandemic (e.g., monoclonal antibodies, antiviral drugs), convalescent plasma is rapidly available, inexpensive to produce, and can be adaptive to viral evolution by selection of contemporary convalescent donors.
Keywords	immune plasma ; convalescent plasma ; COVID-19 ; vaccination
Language	English
Publishing date	2023-02-01
Publisher	Georg Thieme Verlag KG
Publishing place	Stuttgart ; New York
Document type	Article
ZDB-ID	801512-0
ISSN	2567-5761 ; 0720-9355
ISSN (online)	2567-5761
ISSN	0720-9355
DOI	10.1055/a-1987-3682
Database	Thieme publisher's database

In stock of ZB MED Cologne/Königswinter

Zs.A 1631: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: BNT162b2 Vaccination Elicits Strong Serological Immune Responses Against SARS-CoV-2 Including Variants of Concern in Elderly Convalescents.

Jahrsdörfer, Bernd / Fabricius, Dorit / Scholz, Judith / Ludwig, Carolin / Grempels, Aline / Lotfi, Ramin / Körper, Sixten / Adler, Guido / Schrezenmeier, Hubert

Frontiers in immunology

2021 Volume 12, Page(s) 743422

Abstract: Elderly residents of long-term care facilities (LTCFs) have long been underrepresented in studies on vaccine efficacy, particularly in light of currently emerging variants of concern (VOCs). In this prospective observational cohort study, we analyzed ... ...

Abstract	Elderly residents of long-term care facilities (LTCFs) have long been underrepresented in studies on vaccine efficacy, particularly in light of currently emerging variants of concern (VOCs). In this prospective observational cohort study, we analyzed serological immune responses in 190 individuals before, 3 weeks after 1
MeSH term(s)	Adult ; Aged ; Aged, 80 and over ; Antibodies, Neutralizing/blood ; Antibodies, Viral/blood ; COVID-19/immunology ; COVID-19/prevention & control ; COVID-19 Vaccines/immunology ; Convalescence ; Humans ; Immunoglobulin A/blood ; Immunoglobulin G/blood ; Long-Term Care ; Middle Aged ; Prospective Studies ; SARS-CoV-2/immunology ; Vaccination ; Young Adult
Chemical Substances	Antibodies, Neutralizing ; Antibodies, Viral ; COVID-19 Vaccines ; Immunoglobulin A ; Immunoglobulin G ; BNT162 vaccine (N38TVC63NU)
Language	English
Publishing date	2021-09-29
Publishing country	Switzerland
Document type	Journal Article ; Observational Study ; Research Support, Non-U.S. Gov't
ZDB-ID	2606827-8
ISSN	1664-3224 ; 1664-3224
ISSN (online)	1664-3224
ISSN	1664-3224
DOI	10.3389/fimmu.2021.743422
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Differential expression of serpins may selectively licence distinct granzyme B functions including antigen cross-presentation.

Fabricius, Dorit / Trzaska, Timo / Fecher, Theresa / Dimitriou, Evripides / Jahrsdörfer, Bernd

Molecular immunology

2017 Volume 87, Page(s) 325–326

MeSH term(s)	Antigen Presentation ; Antigens ; Cross-Priming ; Granzymes ; Serpins
Chemical Substances	Antigens ; Serpins ; Granzymes (EC 3.4.21.-)
Language	English
Publishing date	2017
Publishing country	England
Document type	Letter ; Comment
ZDB-ID	424427-8
ISSN	1872-9142 ; 0161-5890
ISSN (online)	1872-9142
ISSN	0161-5890
DOI	10.1016/j.molimm.2017.03.004
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 166: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against Omicron subvariants BA.1, BA.2 and BA.5 and can be predicted by anti-S antibody concentrations in serological assays.

Seidel, Alina / Hoffmann, Simone / Jahrsdörfer, Bernd / Körper, Sixten / Ludwig, Carolin / Vieweg, Christiane / Albers, Dan / von Maltitz, Pascal / Müller, Rebecca / Lotfi, Ramin / Wuchter, Patrick / Klüter, Harald / Kirchhoff, Frank / Schmidt, Michael / Münch, Jan / Schrezenmeier, Hubert

Frontiers in immunology

2023 Volume 14, Page(s) 1170759

Abstract: Background: Recent data on immune evasion of new SARS-CoV-2 variants raise concerns about the efficacy of antibody-based COVID-19 therapies. Therefore, in this study the : Methods and findings: The study included 313 serum samples from 155 ... ...

Abstract	Background: Recent data on immune evasion of new SARS-CoV-2 variants raise concerns about the efficacy of antibody-based COVID-19 therapies. Therefore, in this study the Methods and findings: The study included 313 serum samples from 155 individuals with a history of SARS-CoV-2 infection, divided into subgroups without (n=25) and with SARS-CoV-2 vaccination (n=130). We measured anti-SARS-CoV-2 antibody concentrations by serological assays (anti-SARS-CoV-2-QuantiVac-ELISA (IgG) and Elecsys Anti-SARS-CoV-2 S) and neutralizing titers against B.1, BA.1, BA.2 and BA.5 in a pseudovirus neutralization assay. Sera of the majority of unvaccinated convalescents did not effectively neutralize Omicron sublineages BA.1, BA.2 and BA.5 (51.7%, 24.1% and 51.7%, resp.). In contrast, 99.3% of the sera of superimmunized individuals (vaccinated convalescents) neutralized the Omicron subvariants BA.1 and BA.5 and 99.6% neutralized BA.2. Neutralizing titers against B.1, BA.1, BA.2 and BA.5 were significantly higher in vaccinated compared to unvaccinated convalescents (p<0.0001) with 52.7-, 210.7-, 141.3- and 105.4-fold higher geometric mean of 50% neutralizing titers (NT50) in vaccinated compared to unvaccinated convalescents. 91.4% of the superimmunized individuals showed neutralization of BA.1, 97.2% of BA.2 and 91.5% of BA.5 with a titer ≥ 640. The increase in neutralizing titers was already achieved by one vaccination dose. Neutralizing titers were highest in the first 3 months after the last immunization event. Concentrations of anti-S antibodies in the anti-SARS-CoV-2-QuantiVac-ELISA (IgG) and Elecsys Anti-SARS-CoV-2 S assays predicted neutralization capacity against B.1 and Omicron subvariants BA.1, BA.2 and BA.5. Conclusions: These findings confirm substantial immune evasion of the Omicron sublineages, which can be overcome by vaccination of convalescents. This informs strategies for choosing of plasma donors in COVID-19 convalescent plasma programs that shall select specifically vaccinated convalescents with very high titers of anti-S antibodies.
MeSH term(s)	Humans ; SARS-CoV-2 ; COVID-19 Vaccines ; COVID-19/prevention & control ; COVID-19 Serotherapy ; Vaccination ; Antibodies, Viral ; Immunoglobulin G
Chemical Substances	COVID-19 Vaccines ; Antibodies, Viral ; Immunoglobulin G
Language	English
Publishing date	2023-04-25
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2606827-8
ISSN	1664-3224 ; 1664-3224
ISSN (online)	1664-3224
ISSN	1664-3224
DOI	10.3389/fimmu.2023.1170759
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

Order via subito

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito